FIMECS, Inc. is developing a new class of drugs based on emerging modality “Targeted Protein Degradation”. Integrating proprietary E3 ligase binders and RaPPIDS™ platform will enable to address previously considered undruggable targets and to provide game-changing drugs to the patients with high unmet medical needs. To deliver a powerful drug discovery engine, our efforts have focused on identifying novel E3 ligase binders to improve physicochemical properties which can be designed for oral bioavailability. In addition, one of our strong pipelines, an IRAK-M degrader, would provide the first proof-of-concept for targeted protein degradation as a novel and promising immuno-modulatory therapeutic modality. https://www.fimecs.com/eng/ [email protected]